Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, Via Belmeloro, 6, 40126 Bologna, Italy.
Curr Med Chem. 2013;20(13):1639-45. doi: 10.2174/0929867311320130004.
Polypharmacology offers a model for the way drug discovery must evolve to develop therapies most suited to treating currently incurable diseases. It is driven by a worldwide demand for safer, more effective, and affordable medicines against the most complex diseases, and by the failures of modern drug discovery to provide these. Polypharmacology can involve combinations and/or multitarget drugs (MTD). Although not mutually exclusive, my premise is that MTDs have inherent advantages over combinations. This review article focuses on MTDs from a medicinal chemistry perspective. I will explore their use in current clinical practice, their likely application in the future, and the challenges to be overcome to achieve this goal.
多靶标药物疗法为药物研发提供了一种模式，以开发最适合治疗目前无法治愈的疾病的疗法。它是由全球对更安全、更有效和更实惠的药物治疗最复杂疾病的需求以及现代药物研发未能提供这些药物的需求所驱动的。多靶标药物疗法可以涉及组合和/或多靶标药物（MTD）。虽然不是相互排斥的，但我的前提是 MTD 具有内在优势。本文从药物化学的角度聚焦于 MTD。我将探讨它们在当前临床实践中的应用、未来可能的应用以及实现这一目标所面临的挑战。
